New treatment to overpower drug resistance in ovarian cancer

	Tweet

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism. Published today in Autophagy, the researchers found the drug (FTY720) had a potent effect in human ovarian cancer cells, even in those resistant to cisplatin, the most commonly used chemotherapeutic drug currently available for the treatment of ovarian cancer.

Centenary Institute Signal Transduction Head Associate Professor Pu Xia described the findings as a breakthrough in ovarian cancer treatment because, FTY720 kills ovarian cancer cells through a unique way different to the current anti-cancer drugs. Current treatments, such as cisplatin, kill ovarian cancer cells through a way of programming cell death known as apoptosis but this is often reversible or demolished by cancer cells. However, FTY720 kills cells through an irreversible process known as necrosis so the cancer cells cannot resist, repair and relapse.

Each year, around 800 Australian women die from ovarian cancer1, and ovarian cancer remains the leading cause of death in women with gynaecological malignancies over the world. 

Dr Xia said: “One of the major reasons for such a poor outcome of ovarian cancer is that the cancer cells have an ability to resist the current chemotherapeutic drugs through a protective shield, which occurs naturally or as a response to the treatment, and this survives the cancer from the treatment. Such a protective shield, uncovered by the findings from the Xia laboratory, is built, at least partially, on a catabolic process, called autophagy, by which cells eat their own non-vital components for survival under stress conditions such as starvation or chemotherapy. Remarkably, despite this survival process being activated by ovarian cancer cells during the treatment, FTY720 is still capable of killing them effectively.

While this research is a major first step toward developing a more effective treatment for ovarian cancer, the researchers claim more pre-clinical and clinical trials are needed before the drug might be used in women with ovarian cancer. However, the researchers are optimistic that the treatment would be available as a new chemotherapeutic agent within the next several years, because this drug has been approved by the US Food and Drug Administration (FDA) for use in the treatment of multiple sclerosis and is also used in multiple clinical trials for the prevention of organ transplant rejection and the treatment of various autoimmune diseases. Recent studies have also shown anti-tumour efficacy in several types of cancers but this is the first time it has been studied for the treatment of ovarian cancer.

###

This research was made possible by a Research Fellowship from the Cancer Institute New South Wales to Associate Professor Xia. The project also received support from the National Health and Medical Research Council and Science and Technology Council of Shanghai Municipality.

1. Ovarian Cancer Australia.

Media Contact: Tanya Sarina, Communications Manager at the Centenary Institute
p: 02 9565 6228 m: 0431 029 215 e:

About the Centenary Institute: The Centenary Institute is an independent medical research institute, affiliated with Royal Prince Alfred Hospital and the University of Sydney. Our blend of highly skilled staff and state-of-the art equipment and facilities has allowed us to become world leaders in three critical areas of medical research – cancer, cardiovascular disease and infectious diseases.

###
Contact: Tanya Sarina

61-295-656-228
Centenary Institute

RELATED STORIES:
Bloating, pain may precede ovarian cancer   Goodness of milk ‘offset by ovarian cancer risk’   Avastin helps in ovarian cancer but effects fade   Vascular marker of ovarian cancer identified   Discovery May Lead to Turning Back the Clock on Ovarian Cancer   Excess pounds may raise ovarian cancer risk   Study Provides Clues to Prevent Spread of Ovarian Cancer   Study Explains High Platelets in Ovarian Cancer Patients; Survival Reduced   UCI study finds racial, economic disparities in ovarian cancer care, survival   Women with Certain Type of Ovarian Cancer and BRCA Gene Mutation Have Improved Survival at 5 Years   ‘Trojan Horse’ particle sneaks chemotherapy in to kill ovarian cancer cells   Nanotech gene therapy kills ovarian cancer in mice   Researchers identify genes that may help in ovarian cancer diagnosis and prognosis   Early periods may reduce ovarian cancer survival   More study needed on vitamin D-ovarian cancer link   High dairy diet may up ovarian cancer risk   Specialists provide best outcome for ovarian cancer   Proteins show promise for ovarian cancer screening   Survivors of Rare Ovarian Cancer Retain Fertility, Have Positive Relationships   Protein compels ovarian cancer cells to cannibalize themselves   65% of ovarian cancer cells sideline body’s defences   Extracellular protein sensitizes ovarian cancer cells to chemotherapy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]